EGFR News

News

First-Line Osimertinib for Patients With Metastatic NSCLC Harboring Uncommon EGFR Mutations

12/12/2023

Stephanie Holland

Results from the nonrandomized, phase 2 UNICORN trial demonstrated that first-line osimertinib is a clinically effective and safe treatment option for patients with metastatic non-small cell lung cancer harboring an uncommon EGFR mutation.

Results from the nonrandomized,...

12/12/2023

Oncology

News

Patritumab Deruxtecan for Patients With Previously Treated, EGFR-Mutated Non-Small Cell Lung Cancer

10/18/2023

Stephanie Holland

Results from the phase 2 HERTHENA-Lung01 trial found that patritumab deruxtecan is clinically durable and effective for patients with previously treated EGFR-mutated NSCLC.

Results from the phase 2...

10/18/2023

Oncology

News

Amivantamab Plus Chemotherapy Provides PFS Benefit in EGFR-Mutated NSCLC

09/11/2023

Stephanie Holland

According to Janssen Pharmaceutical Companies of Johnson & Johnson, amivantamab with or without lazertinib plus chemotherapy significantly improves progression-free survival among patients with EGFR-mutated NSCLC.

According to Janssen...

09/11/2023

Oncology

News

Lazertinib as Another First-Line Option for Patients With EGFR-Mutated, Advanced NSCLC

08/02/2023

Stephanie Holland

According to results from the phase 3 LASER301 trial, lazertinib significantly improved efficacy compared to gefitinib among patients with treatment-naïve EGFR-mutated advanced NSCLC, with a manageable safety profile.

According to results from the...

08/02/2023

Oncology

News

Zipalertinib Displayed Promising Preliminary Antitumor Activity Among Patients With EGFR-Mutant NSCLC

07/24/2023

Stephanie Holland

According to results of a phase 1/2a study, zipalertinib demonstrated promising preliminary antitumor activity with acceptable safety among patients with heavily pretreated EGFR ex20ins-mutant NSCLC.

According to results of a phase...

07/24/2023

Oncology

News

Amivantamab Added to Chemotherapy Improves PFS Among Patients With Non-Small Cell Lung Cancer With EGFR Mutation

07/20/2023

Allison Casey

According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.

According to Janssen...

07/20/2023

Oncology

News

Adjuvant Osimertinib Significantly Improved Overall Survival Among Patients With EGFR-Mutated NSCLC

07/10/2023

Stephanie Holland

According to final analysis results from the phase 3 ADAURA trial, adjuvant osimertinib significantly improved overall survival among patients with completely resected EGFR-mutated, stage 1B-2A NSCLC.

According to final analysis...

07/10/2023

Oncology

News

Concurrent Osimertinib and Chemotherapy for First-line EGFR-Mutated NSCLC

05/25/2023

A phase 2 trial confirmed the safety and efficacy of concurrent osimertinib and platinum-based chemotherapy in patients with previously untreated EGFR-mutated non-small cell lung cancer.

A phase 2 trial confirmed the...

05/25/2023

Oncology

News

Osimertinib for Patients With Progressive EGFR-Mutated T790M-Negative NSCLC

04/21/2023

Derek Cowsert

Osimertinib demonstrated modest antitumor activity in patients with EGFR-mutated T790M-negative non-small cell lung cancer that has progressed after treatment, according to a phase 2 study.

Osimertinib demonstrated modest...

04/21/2023

Oncology

News

EGFR Mutation Prevalence in Non-Small Cell Lung Cancer in West-European Patient Population

03/09/2023

Derek Cowsert

The prevalence of EGFR mutations in West-European patients with non-small cell lung cancer were found to be statistically substantial.

The prevalence of EGFR mutations...

03/09/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology